7EY0 Stock Overview
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Kiora Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.47 |
| 52 Week High | US$2.66 |
| 52 Week Low | US$0.40 |
| Beta | -0.26 |
| 1 Month Change | -9.56% |
| 3 Month Change | -30.39% |
| 1 Year Change | -82.02% |
| 3 Year Change | -99.63% |
| 5 Year Change | -99.61% |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7EY0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 13.6% | 1.5% | -0.5% |
| 1Y | -82.0% | -27.9% | 2.5% |
Return vs Industry: 7EY0 underperformed the German Pharmaceuticals industry which returned -27.9% over the past year.
Return vs Market: 7EY0 underperformed the German Market which returned 2.5% over the past year.
Price Volatility
| 7EY0 volatility | |
|---|---|
| 7EY0 Average Weekly Movement | 17.4% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7EY0's share price has been volatile over the past 3 months.
Volatility Over Time: 7EY0's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 12 | Brian Strem | www.kiorapharma.com |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair.
Kiora Pharmaceuticals, Inc. Fundamentals Summary
| 7EY0 fundamental statistics | |
|---|---|
| Market cap | €13.26m |
| Earnings (TTM) | -€12.14m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs 7EY0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7EY0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$4.03m |
| Gross Profit | -US$4.03m |
| Other Expenses | US$9.02m |
| Earnings | -US$13.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 7EY0 perform over the long term?
See historical performance and comparison